以上内容基于公开资料整理，不构成投资建议。 经济观察网艾迪药业计划以简易程序向特定对象发行A股股票，拟募集资金不超过1.85亿元，用于收购 控股子公司南京南大药业少数股东股权及补充流动资金，该事项尚需上海证券交易所审核通过及中国证 监会注册。同时，公司拟以约1.3亿元收购南大药业22.2324%的股权，交易完成后持股比例将从 51.1256%增至73.358%，目前尚需市场监督管理部门核准。此外，董事会已审议通过相关议案，但暂不 召开股东大会，将根据整体工作安排适时召开。公司在研产品如AD108注射液和注射用ADB116的研发 工作也在持续推进中。 ...

Core Viewpoint - Jiangsu Aidi Pharmaceutical (688488.SH) announced a plan to acquire minority shareholder equity in its subsidiary, Nanjing Nanda Pharmaceutical, which will increase its direct shareholding from 51.13% to 73.36% [1][3] Group 1: Acquisition Details - Aidi Pharmaceutical plans to raise up to 185 million yuan through a simplified procedure to fund the acquisition, with 130 million yuan allocated for acquiring 22.23% of Nanda Pharmaceutical's equity and 55 million yuan for working capital [1] - The acquisition is expected to enhance Aidi's control over Nanda Pharmaceutical and optimize financial performance, maximizing synergies between the two companies [4][10] Group 2: Market Potential - The demand for stroke treatment is anticipated to surge, with acute ischemic stroke cases in China projected to rise from 4.1 million in 2023 to 4.9 million by 2027 [4] - The market for neuroprotective drugs in China is expected to grow from 11.5 billion yuan in 2024 to 16.9 billion yuan by 2030, and further to 26.2 billion yuan by 2035 [4] Group 3: Product Pipeline - Aidi's new drugs, AD108 injection and ADB116 injection, are positioned to become significant profit growth drivers, targeting acute ischemic stroke treatment [4] - Aidi's HIV drug, Enomirac, has shown strong sales potential, with revenue from HIV drugs reaching 211 million yuan in the first three quarters of 2025, a 57.12% increase year-on-year [6][7] Group 4: International Expansion - Aidi Pharmaceutical is accelerating its international market expansion, with its HIV drug Enomirac approved for sale in Zanzibar, marking a significant milestone for Chinese-developed HIV drugs in Africa [9] - The company is also advancing its pipeline of innovative drugs, including a new HIV integrase inhibitor and long-acting pre-exposure prophylaxis drugs, which are in various stages of clinical trials [10]

Core Viewpoint - The acquisition of an additional 22.2324% stake in Nanjing Nanda Pharmaceutical by Aidi Pharmaceutical strengthens its control and supports its integrated strategy in human-derived protein production and formulation [1][2]. Group 1: Acquisition Details - Aidi Pharmaceutical announced the acquisition of 22.2324% of Nanjing Nanda Pharmaceutical for 130.05954 million yuan, increasing its ownership from 51.1256% to 73.3580% [1]. - This acquisition is aimed at solidifying control and enhancing the implementation of the company's integrated strategy in human-derived protein [2]. Group 2: Strategic Benefits - The acquisition is expected to reinforce strategic management, enhance resource synergy, and improve operational efficiency by integrating production, channels, and platforms [2]. - The financial performance of Nanjing Nanda Pharmaceutical has shown steady growth, with revenues of 299 million yuan and net profits of 51.5177 million yuan in 2024, and 262 million yuan in revenue with net profits of 55.8111 million yuan from January to October 2025 [2]. Group 3: R&D Achievements - Following the previous acquisition, Aidi Pharmaceutical and Nanjing Nanda Pharmaceutical have successfully developed two human-derived protein drugs, AD108 and ADB116, which have received IND approval [3][4]. - These drugs are designed to meet clinical needs, with AD108 offering a subcutaneous delivery method and ADB116 providing a rapid intravenous administration option for acute ischemic stroke [4]. Group 4: Market Potential - The human-derived protein market, particularly for ischemic stroke treatment, is significant, with approximately 3.4 million new stroke cases annually in China, 80% of which are ischemic strokes [5]. - The market for ischemic stroke treatments is projected to grow, with a 2023 market size of approximately 12.9 billion yuan, indicating substantial opportunities for Aidi Pharmaceutical's new products [5]. Group 5: Future Outlook - Aidi Pharmaceutical plans to leverage this acquisition to deepen resource integration with Nanjing Nanda Pharmaceutical, accelerating the development of its human-derived protein pipeline [6]. - The company aims to capitalize on industry growth and enhance its position in the human-derived protein sector, contributing to high-quality development in the biopharmaceutical industry [6].

Group 1 - The company, Jiangsu Aidi Pharmaceutical Group Co., Ltd., plans to raise up to 185 million yuan through a simplified procedure to issue A-shares, primarily to acquire a 22.23% stake in its subsidiary, Nanjing Nanda Pharmaceutical Co., Ltd., for approximately 130 million yuan, and to supplement working capital with 55 million yuan [1] - Nanda Pharmaceutical specializes in thrombolytic drugs and low molecular weight heparin raw materials, making it one of the few integrated manufacturers in China holding production approvals for both raw materials and injectable formulations [2] - The acquisition of Nanda Pharmaceutical is expected to enhance the company's control over it, optimize financial performance, and maximize synergies, thereby strengthening its competitive position in the human protein sector [3] Group 2 - The stroke incidence in China is rising, with acute ischemic stroke cases projected to increase from 4.1 million in 2023 to 4.9 million by 2027, highlighting a significant unmet clinical need for effective stroke treatments [3] - The market for neuroprotective drugs in China is expected to grow from 11.5 billion yuan in 2024 to 16.9 billion yuan by 2030, and further to 26.2 billion yuan by 2035, indicating a strong demand for innovative stroke medications [3] - Aidi Pharmaceutical has maintained rapid growth in the HIV sector for three consecutive years, with the market for anti-HIV drugs in China estimated at 7 billion yuan in 2023, projected to exceed 11 billion yuan by 2027 [4] Group 3 - The company is advancing its core HIV pipeline and aims to establish a comprehensive commercialization system for new HIV drugs, addressing the significant challenge posed by the large population of HIV-infected individuals in China [4] - Aidi Pharmaceutical has made significant progress in its HIV drug pipeline, with new drugs like ACC017 and ADC118 entering clinical trials, and is also developing long-acting pre-exposure prophylaxis drugs [5] - The 55 million yuan raised will be used to support operational funding and accelerate the development of core research projects, ensuring the efficient rollout of a diverse and comprehensive HIV drug commercialization strategy [5]

Core Insights - In 2024, domestic innovative drugs, particularly in the HIV sector, are experiencing new growth opportunities driven by national policy support and market demand recovery [2][3] - The company, Aidi Pharmaceutical, is focused on overcoming key technical barriers in the HIV field and aims to provide safe and effective medication options for domestic patients [2][3] Sales Performance - In 2024, the total sales revenue from HIV new drugs reached approximately 149.9 million yuan, representing a year-on-year growth of 103.73% [3][8] - In the first quarter of 2025, the revenue from HIV new drugs was 62.7 million yuan, showing a year-on-year increase of 75.64%, marking a historical high for a single quarter [2][3] Academic Contributions - The company presented the results of the SPRINT study at the 10th National AIDS Academic Conference, demonstrating the long-term value of its drug, Ainomi [4] - The treatment adherence and viral suppression rates for Ainomi in the continuous treatment group were above 95% over 144 weeks, indicating its safety and effectiveness [4] Research and Development - In 2024, the company invested 107.5 million yuan in R&D, a 27.71% increase year-on-year, accounting for 25.73% of its revenue [5] - The company is advancing its pipeline with various projects, including the ACC017 tablet in Phase II clinical trials and long-acting innovative HIV drugs [5] Strategic Partnerships - The company acquired control of Nanda Pharmaceutical to integrate upstream and downstream resources, enhancing its "HIV new drug + human protein" dual strategy [6] - In 2024, Nanda Pharmaceutical achieved a revenue of 298.6 million yuan and a net profit of 51.5 million yuan, with continued collaboration expected to accelerate clinical trials for new drugs [6] Financial Performance - In 2024, the company reported total revenue of 417.8 million yuan, with a net loss of 141.2 million yuan [8] - In the first quarter of 2025, the company achieved revenue of 197.9 million yuan and a net profit of 1.6 million yuan, indicating a positive start to the year [8]